Pfizer Says Developed Coronavirus Vaccine Candidate With Over 90 percent Success Rate


US pharmaceutical giant Pfizer announced Monday its coronavirus vaccine candidate was more than 90 percent effective in preventing Covid-19, based on the results of the latest trials.

"Vaccine candidate was found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysis," the company said in a press release.

The vaccine was developed by Pfizer and BioNTech SE. According to the press releave, the "mRNA-based vaccine candidate, BNT162b2, against SARS-CoV-2 has demonstrated evidence of efficacy against COVID-19 in participants without prior evidence of SARS-CoV-2 infection, based on the first interim efficacy analysis conducted on November 8, 2020 by an external, independent Data Monitoring Committee (DMC) from the Phase 3 clinical study."

Current Issue